scLT-kit automates barcode-quality check, fate metrics & clone-transcriptome mapping, revealing normal vs. drugged cell dynamics across hematopoiesis, C. elegans, and cancer

Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart Mipitecan (LY4170156), a Novel ADC Targeting Folate Receptor Alpha (FRα), in Recurrent Ovarian Cancer

 

The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3133, a pivotal Phase 3 clinical trial titled FRAmework-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. The study is sponsored by Eli Lilly and Company and conducted in collaboration with The GOG Foundation, Inc.

MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches across all sgRNA positions with near-zero off-target activity. By selectively removing wild-type DNA before sequencing, it boosts true mutant signals up to tens of times and enables detection as low as ~0.005% VAF. The technique improves MRD monitoring and early-stage cancer detection while avoiding the need for costly ultra-deep sequencing.

When cell division (mitosis) takes too long, it can be a sign that something is wrong with the cells, for example DNA damage or chromosomal instability. That’s why our cells come with an innate ability to tell the time, with a stress response known as the mitotic stopwatch pathway activating after prolonged mitosis. Now, researchers at the Okinawa Institute of Science and Technology (OIST) have found that certain cancers can ‘lose their sense of time’ to avoid cellular stress responses, revealing new insights that could shape future anti-cancer therapeutics.